Key result
Intraperitoneal cisplatin and paclitaxel linked to severe hypertriglyceridemia, peaking at ~1870 mg/dL.
Why the study?
Severe hypertriglyceridemia is a rare adverse event that had not been reported in the literature with intraperitoneal cisplatin and paclitaxel.
Case Report (n=1)
No
Intravenous and intraperitoneal cisplatin and paclitaxel can precipitate severe hypertriglyceridemia (>1800 mg/dL) in patients with mild baseline dyslipidemia, warranting lipid monitoring and medical management with fibrates and statins to mitigate pancreatitis and cardiovascular risk while completing chemotherapy.
May warrant lipid monitoring during intraperitoneal cisplatin-paclitaxel; extends prior reports but remains hypothesis-generating.
This case report describes a patient who developed severe hypertriglyceridemia (1871 mg/dL) and hyperlipidemia (LDL 132 mg/dL) during intraperitoneal (IP) administration of cisplatin and paclitaxel as adjuvant treatment for stage IIIC fallopian tube carcinoma. After an evaluation with her primary care physician, she was treated with gemfibrozil and rosuvastatin for the duration of her treatment. There was complete resolution of hypertriglyceridemia after completion of chemotherapy. This adverse event is rare and has not been reported in the literature with this chemotherapeutic regimen. A pre-chemotherapy evaluation for dyslipidemia may be beneficial in the detection and monitoring of this condition.
No takes yet. Share an insight, caveat, or question.
Lander et al. (2020) conducted a case report in Stage IIIC fallopian tube carcinoma with severe chemotherapy-associated hypertriglyceridemia (n=1). Intravenous and intraperitoneal cisplatin and paclitaxel followed by gemfibrozil, rosuvastatin, and metformin was evaluated on Serum triglyceride levels. Intraperitoneal cisplatin and paclitaxel was associated with severe hypertriglyceridemia (1871 mg/dL), which resolved to 153 mg/dL with gemfibrozil and rosuvastatin and completion of chemotherapy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: